Sugi Predict

Sugi Predict / Compounds / SCHEMBL7175462

SCHEMBL7175462

SCHEMBL7175462

COc1cc(OC)c(C(=O)[P](=O)c2ccccc2C(=O)c2c(Cl)cccc2Cl)c(OC)c1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 3/20 0.45
▸ ABCG2 Q9UNQ0 3/20 0.43
▸ LMNA P02545 2/20 0.41
▸ TOP1 P11387 1/20 0.40
▸ MAPT P10636 2/20 0.39
▸ CES2 O00748 1/20 0.39
▸ CES1 P23141 1/20 0.39
▸ ELANE P08246 1/20 0.38
▸ RORC P51449 1/20 0.38
▸ ATM Q13315 2/20 0.37
▸ NPC1 O15118 1/20 0.37
▸ POLB P06746 1/20 0.37
▸ CASP3 P42574 1/20 0.37
▸ SENP8 Q96LD8 1/20 0.37
▸ SENP7 Q9BQF6 1/20 0.37
▸ SENP6 Q9GZR1 1/20 0.37
▸ MEN1 O00255 1/20 0.37
▸ TUBB4A P04350 1/20 0.36
▸ TUBB P07437 1/20 0.36
▸ TUBA3C P0DPH7 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7182106 0.95 KMT2A (0.45) KMT2AABCG2LMNATOP1MAPT
SCHEMBL7184065 0.92 KMT2A (0.41) KMT2AABCG2LMNAMAPTCES2
SCHEMBL7186470 0.91 RORC (0.42) KMT2ALMNACES2CES1RORC
SCHEMBL7180936 0.91 KMT2A (0.40) KMT2AABCG2LMNATOP1MAPT
SCHEMBL7178126 0.89 KMT2A (0.41) KMT2AABCG2LMNATOP1MAPT
SCHEMBL7182505 0.89 KMT2A (0.40) KMT2AABCG2LMNAMAPTATM
SCHEMBL7188977 0.89 MAPT (0.41) KMT2AABCG2MAPTATMNPC1
SCHEMBL7736110 0.87 ALDH1A1 (0.43) KMT2AABCG2MAPTATMNPC1
SCHEMBL7183314 0.86 ABCG2 (0.48) KMT2AABCG2LMNATOP1MAPT
SCHEMBL7185481 0.86 NPC1 (0.40) KMT2AABCG2MAPTATMNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6579663-B2 Chemical intermediates such as lithium 2,6-dimethylbenzoyl phenylphosphine for preparation of acylphosphines, acylphosphine oxides or acylphosphine sulfides CIBA SPECIALTY CHEMICALS CORPORATION 2003-06-17 — — US disclosed
US-20020107413-A1 Organometallic monoacylarylphosphines WOLF JEAN-PIERRE (CH) 2002-08-08 — — US disclosed
US-6399805-B2 SUCH AS LITHIUM 2,6-DIMETHYLBENZOYLPHENYLPHOSPHINE, USE AS PHOTOINITIATORS IN PHOTOCURABLE COMPOSITIONS SUCH AS FOR PHOTOGRAPHIC PRODUCTION OF RELIEF IMAGES CIBA SPECIALTY CHEMICALS CORPORATION 2002-06-04 — — US disclosed
US-20010031898-A1 Organometallic monoacylarylphosphines CIBA SPECIALTY CHEMICALS CORP. 2001-10-18 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020107413-A1 Organometallic monoacylarylphosphines CBR1, NAF1, DHCR24 KMT2A 1586/4885ABCG2 3732/4885LMNA 3241/4885
US-20010031898-A1 Organometallic monoacylarylphosphines NAF1, DHCR24, CBR1 KMT2A 956/4885ABCG2 4323/4885LMNA 3247/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.